A concomitant ATP-depleting strategy markedly enhances anticancer agent activity

Apoptosis : an International Journal on Programmed Cell Death
D S MartinJ A Koutcher

Abstract

Most anticancer agents effect DNA damage which initiate the cell death pathways of necrosis and apoptosis, but cancer cells of lesser sensitivity are only sublethally injured, and recover. The two death pathways and their interelationships in the presence of endogenous inhibitors of apoptosis and genetic deletions that facilitates only sublethal damage, are reviewed. Both ATP and pyrimidine levels in the sublethally injured cancer cells are reduced but not to low levels insuffient to sustain cell viability. However, this sublethal damage by the anticancer agent creates a therapeutic opportunity for further reduction of these key metabolites to lower levels that will not support life. Data in tumor-bearing animals is reviewed demonstrating that a combination of ATP-depleting agents plus a de novo pyrimidine inhibitor (PALA) administered concomitantly with each of nine different anticancer agents markedly enhances tumor regression rates,and even produces some cures. It is necessary to deplete tumor ATP levels seveerely (>85%) by a combination of agents that block both synthesis (6-methylmercaptopurine riboside, a purine de novo synthesis inhibitor) and generation of ATP(6-aminonicotinamide, an inhibitor of glycolysis.) Cell viabi...Continue Reading

Citations

Jan 4, 2003·Photochemistry and Photobiology·Christian Benno OberdannerKristjan Plaetzer
Aug 8, 2006·Oncogene·H PelicanoP Huang
Oct 20, 2006·Proceedings of the National Academy of Sciences of the United States of America·Mukesh K AgarwalMunna L Agarwal
Apr 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Kedar HastakMunna L Agarwal
Nov 28, 2012·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Verena SchneiderGanna V Kalayda
Aug 17, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sangiliyandi GurunathanJin-Hoi Kim
May 27, 2003·Biopolymers·Barry S Cooperman
Jun 26, 2013·Purinergic Signalling·Geoffrey Burnstock, Francesco Di Virgilio
Oct 3, 2013·Metallomics : Integrated Biometal Science·K Benjamin Garbutcheon-SinghJanice R Aldrich-Wright
Jul 5, 2006·Molecular Cancer Therapeutics·Wan Seok YangChul-Woo Kim
Sep 6, 2005·Cancer Research·Ajin WangArthur B Pardee
May 4, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Manickam MuruganandhamJason A Koutcher
Aug 2, 2005·Advances in Enzyme Regulation·Barry S CoopermanJaskiran Kaur
May 15, 2007·The International Journal of Biochemistry & Cell Biology·Robert A Gatenby, Robert J Gillies
Feb 5, 2008·Biochemical Pharmacology·Laurent Bastin-CoyetteFrançoise Bontemps
Oct 19, 2010·Medical Hypotheses·Edward Henry MathewsRuaan Pelzer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis